GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

FluoroPharma Medical FPMI · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About FluoroPharma Medical

Its shares trade under the ticker FPMI. It has been listed since 18 August 2008.

FluoroPharma Medical, Inc. engages in the research, development, and commercialization molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company is headquartered in Montclair, New Jersey. The company went IPO on 2008-08-18. The firm operates through biopharmaceutical research and development segment. The company is focused on the development of cardiovascular imaging agents that can detect and assess acute and chronic forms of coronary artery disease (CAD). The company has two clinical-stage molecular imaging pharmaceutical product candidates: Flourine-18 (18-F) TPP (BFPET), which includes a ((18F)-labeled cationic lipophilic tetraphenylphosphonium ion (18-F TPP) as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD, and 18-F FCPHA (CardioPET), which includes Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid (18-F FCPHA) as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
18 Aug 2008
Employees
4

Leadership

Pay as last reported

  • Mr. Walter WitoshkinIndependent interim chairman of the board, since 2011
  • Mr. Ambrose EgbuonuPresident, Treasurer, Company Secretary
  • Dr. Thomas TulipChief Executive Officer, Director, since 2015$320,000
  • Mr. Frank IgwealorChief Financial Officer, Controller, Director, since 2022
  • Mr. William LewisIndependent Director
  • Richard MoyerIR Contact Officer of Cameron Associates, Inc.

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • FluoroPharma Medical Inc possesses several key strengths that contribute to its competitive advantage in the market. These include:

Weaknesses

  • FluoroPharma Medical Inc faces certain weaknesses that may hinder its performance and market position. These weaknesses include:

Opportunities

  • FluoroPharma Medical Inc can leverage several opportunities to enhance its market position and growth prospects. These opportunities include:

Threats

  • FluoroPharma Medical Inc encounters several threats that may pose challenges to its success and profitability. These threats include:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.